Member Info for tkevin

What do you base your suspicions and thoughts on Roger? I’m assuming nothing, like usual.

It allowed you months to get out if you thought it was a bad idea unlike a capital raise which you hear about at 7am and you’re fully diluted

Gloria - why do you say he was successful? He did a fundraise that peelhunt had to buy into to get it over the line and nice was done and submitted by budd . I don’t see that he achieved anything at all even the tiniest thing at all

That’s a great way to get value out of your stock options is to leave a company just as it’s about to do well. Why post such nonsense

Johnhenry youre a moron mate not a clue

Budd wansnt fired he left the company the most annoying part about cheeky is he will be on a 6 month notice and will be paid until 2025 after doing nothing for eleven months

Leaving by mutual agreement is not something that happens quickly its a discussion and argument over months so all the while NICE was being achieved cheek knew he was on the out. all this I thing reflects really badly on chairman gilham as he obviously hired someone that was out of his depth from day one middle manager type. never run a business and really when you look at it just did back office paper pushing jobs his whole life. anyone that thought he was going to be great needs to go back and read your posts and ask yourself why you thought that or if you were just a typical ramper.

I’m in.

Ask ChatGPT more clever than 99% people on lse

Genedrive's sales strategy for 2024 focuses on several key areas aimed at accelerating growth and expanding their market presence. These include:

Maximizing In-Market Sales: Genedrive aims to boost sales of its flagship products, particularly the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit. The MT-RNR1 kit, used to prevent antibiotic-induced hearing loss in newborns, and the CYP2C19 kit, which helps tailor treatment for stroke patients, are central to their strategy. These products are designed for rapid, point-of-care genetic testing, making them highly relevant in time-critical medical settings.

Geographic Expansion: The company is actively working on expanding its geographical footprint. Initial orders for their products have already been placed in countries like France, Austria, the Netherlands, Greece, Saudi Arabia, and Turkey. This international focus is expected to drive further sales growth as they enter new markets.

Regulatory Approvals and Recommendations: Achieving and leveraging regulatory endorsements is a significant part of their strategy. For instance, the UK's National Institute for Health and Care Excellence (NICE) has recommended the Genedrive® CYP2C19-ID Kit in draft guidance, which is anticipated to be finalized soon. Such endorsements enhance credibility and facilitate adoption in clinical settings​

Portfolio Expansion and Strategic M&A: Genedrive plans to expand its product portfolio through internal development and potential mergers and acquisitions. This approach is intended to diversify their offerings and address more areas within the molecular diagnostics market​

Collaboration with Health Networks: Collaborations with health networks and academic institutions, such as the University of Manchester and Manchester University NHS Foundation Trust, play a crucial role. These partnerships help validate their products in real-world clinical settings, thereby supporting broader commercial adoption​

By focusing on these strategic areas, Genedrive aims to enhance its market position, drive sales growth, and ultimately improve clinical outcomes through innovative genetic testing solutions.

ChatGPT

Just floating in to remind everyone that he’s called Rogered for a reason, listen to at your peril.

And Lloyd - What to do.

Systemzero You don’t have to “think” I’m wrong, you just need to read the NICE website on EVA and what the outcomes are. There’s no outcome of NICE EVA that is unconditional full approval. Pretending there was some possibility of it is wrong or lying.

Brightly1 GDR isn’t a pharmaceutical company and you can count on one hand the number of diagnostic companies that have been purchased in the last 20 years by Pharma. This is a pointless pipe dream you are playing. Either you’re trying to stir the pot or you have no idea what you’re saying.

Systemzero - you have a short memory NICE recommendation was always going to require us to generate more data because that’s the way NICEs early evaluation process works. It’s for products that are new and NICE always makes recommendations based on a lot of real world data which doesn’t exist for new products. So if you are reflecting back on NICEs decision, then you didn’t do your homework and what the process was. GDR did everything correct and received the highest recommendation possible at that point in time.

M. McNulty - finally and thank you - someone here actually understands how a corporate broker works with an equity markets team.

It’s amazing the number of posters here going on and on about peel hu t that haven’t a clue, and people seem to actually listen to their opinion like it’s worth something

budd didn’t csuse a **** show during covid this board did,

Systemzeros’s company analysis is provided by a random number generator

If they’re “held on the re platform until sold” then they don’t have a buyer and peel hunt is the owner.

They’re the broker to the company so they will hold the executives shares 1.6 million is nothing nowadays

Anyone gathering insight from Rogers65 needs to have their head checked.